Research programme: Filovirus immunotherapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: Filovirus immunotherapeutics - Inovio Pharmaceuticals

Alternative Names: dMAb - Inovio; INO 4200; Protein based therapeutic monoclonal antibody - Inovio; VGX 4200

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Ebola virus infections

Highest Development Phases

  • Preclinical Ebola virus infections
  • No development reported Marburg virus disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Marburg virus disease(Prevention) in USA (Intradermal)
  • 08 Apr 2015 Preclinical trials in Ebola virus infections in USA (Parenteral)
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top